

## List of Figures

Figure no.	Description	Page no.
<b>Figure 2.1</b>	Chemical structure of Silver Silfadiazine	<b>36</b>
<b>Figure 5.1</b>	Calibration curve of SSD in water for UV spectrophotometry	<b>56</b>
<b>Figure 5.2</b>	Calibration curve of SSD in phosphate buffer pH 6.8 for UV spectrophotometry	<b>57</b>
<b>Figure 5.3</b>	Software generated 3D plot expressing the effect of various factors on the PS and %EE.	<b>60</b>
<b>Figure 5.4</b>	SEM micrograph of optimized SSD-SLNs	<b>61</b>
<b>Figure 5.5</b>	<i>In-vitro</i> drug release profile of SSD-SLNs in phosphate buffer pH 6.	<b>62</b>
<b>Figure 5.6</b>	FT-IR peaks corresponding to the functional groups of the SSD	<b>63</b>
<b>Figure 5.7</b>	Overlapped FT-IR spectrum of SSD, compritrol 888 ATO, Lutrol F 68, and SSD-SLNs	<b>63</b>
<b>Figure 5.8</b>	DSC thermograms of SSD, physical mixture and SSD-SLNs showing effect of excipients and formulation on melting of SSD	<b>64</b>
<b>Figure 5.9</b>	X-ray diffraction patterns of SSD, physical mixture, and SSD-SLNs	<b>65</b>
<b>Figure 5.10</b>	The graph indicates the comparative inhibition of established <i>P. aeruginosa</i> biofilm after three consecutive dosing (once a day) of pure SSD or encapsulated SSD (18.75 µg/mL) with or without DNase-I (20 µg/mL). A repeated measure two way ANOVA was performed (*, P<0.05, versus non-treated biofilms (0 h); #, P<0.05, versus SSD-SLNs+DNase-I on 72 h). The viable counts $2.3 \times 10^9 \pm 9.1 \times 10^7$ cfu/mL in untreated biofilm was taken as hundred percent	<b>68</b>
<b>Figure 5.11</b>	CLSM images of <i>P. aeruginosa</i> biofilm treated with	<b>69</b>

different test sample (40X magnification). Green fluorescent (SYTO9) cell indicated the Live bacterial cell and red fluorescent (PI) for dead cell. **(i)** Untreated *P. aeruginosa* biofilm, **(ii)** pure SSD, **(iii)** SSD+DNase-I, **(iv)** SSD-SLNs **(v)** SSD-SLNs+DNase-I. (SSD equivalent to 18.75µg/mL and DNase-I equivalent to 20 µg/mL)

<b>Figure 5.12</b>	Bar graph represents the percentage viable dermal fibroblast incubated with varying concentration of pure and encapsulated SSD after 24 h. A repeated measure two way ANOVA was performed (a, P<0.05, vs pure SSD; b, P<0.05, vs SSD+DNase-I)	<b>70</b>
<b>Figure 5.13</b>	<b>(A)</b> Comparative burn wound healing images of rats after 21 days; & <b>(B)</b> Histopathology of re-epithelialized rat skin after 21 days treatment showing at 10X magnification; The treatment group includes: <b>(i)</b> Untreated (diseased control); <b>(ii)</b> SSD marketed cream; <b>(iii)</b> SSD-SLNs chitosan gel; <b>(iv)</b> SSD-SLNs+DNase-I chitosan gel	<b>73</b>
<b>Figure 6.1</b>	Calibration curve of ciprofloxacin in water for UV spectrophotometry	<b>86</b>
<b>Figure 6.2</b>	Calibration curve of ciprofloxacin in phosphate buffer saline pH 6.8 for UV spectrophotometry	<b>87</b>
<b>Figure 6.3</b>	% free amino groups remained after conjugation in AgLase-CIPR-CH-NPs	<b>88</b>
<b>Figure 6.4</b>	% hydrolytic activity of the AgLase-CIPR-CH-NPs after conjugation compared to pure AgLase	<b>88</b>
<b>Figure 6.5</b>	SEM micrograph of the CIPR-CH-NPs	<b>90</b>
<b>Figure 6.6</b>	SEM micrograph of AgLase-CIPR-CH-NPs	<b>90</b>
<b>Figure 6.7</b>	Comparative <i>in vitro</i> release profile of CIPR-CH-NPs and CIPR	<b>92</b>
<b>Figure 6.8</b>	Schematic representation of FTIR peaks on the ciprofloxacin structure	<b>93</b>
<b>Figure 6.9</b>	FTIR spectra of the different test samples	<b>93</b>

<b>Figure 6.10</b>	XRD diffraction pattern of the different formulation	<b>94</b>
<b>Figure 6.11</b>	The comparative findings of the MBIC after 24 h treatment	<b>97</b>
<b>Figure 6.12</b>	The comparative findings of the MBIC after 48 h treatment	<b>98</b>
<b>Figure 6.13</b>	Antimicrobial studies. A and B represents the MBIC after 24 and 48 h. The microbial count in control group was $1.8 \times 10^8 \pm 9.8 \times 10^6$ CFU/ml after 24 h and $2.9 \times 10^9 \pm 1.9 \times 10^8$ CFU/ml after 48h. Moreover, C and D illustrated the results of MBEC study showing reduction of 48 h grown <i>P. aeruginosa</i> biofilm on single dose at different CIPR concentrations and on repeated dosing of formulations ( $0.125\mu\text{g/ml}$ ) for three consecutive days respectively. Two way ANOVA was performed (where * representing $p < 0.05$ ; other groups vs AgLase-CIPR-CH-NPs). The viable count in the controlled experiments without any treatment was $2.45 \times 10^9 \pm 1.23 \times 10^8$ CFU/ml	<b>100</b>
<b>Figure 6.14</b>	CLSM images of biofilm showing the relative density of biofilm. Where A, B, C, D, E and F denote Control or untreated, CIPR, CIPR+AgLase, CIPR-CH-NPs, CIPR-CH-NPs+AgLase and AgLase-CIPR-CH-NPs treated biofilm of <i>P. aeruginosa</i> , respectively	<b>102</b>
<b>Figure 6.15</b>	Bar graph elaborates the findings of the in vitro cytotoxicity study	<b>103</b>
<b>Figure 6.16</b>	% haemolysis after incubating the processed blood sample with formulations.	<b>104</b>
<b>Figure 6.17</b>	Platelet count in blood after treatment with different formulation at different concentration ( $0.0625$ , $0.125$ and $0.25\mu\text{g/ml}$ )	<b>105</b>
<b>Figure 6.18</b>	Leishman's stained microscopic images of whole blood samples after treating with PBS equivalent to $0.0625$ , $0.125$ , and $0.25\mu\text{g/ml}$ of test sample (a, b and c resp.); CIPR at $0.0625$ , $0.125$ , and $0.25\mu\text{g/ml}$ concentration (d, e and f resp.); AgLase at $10$ , $50$ and $100\mu\text{g/ml}$ concentration (g, h and I resp.); CIPR-CH-NPs equivalent	<b>106</b>

to 0.0625, 0.125, and 0.25 $\mu$ g/ml CIPR concentration (j, k and l resp.) and: AgLase-CIPR-CH-NPs equivalent to 0.0625, 0.125, and 0.25 $\mu$ g/ml CIPR concentration (m, n and o resp.)

**Figure 6.19** HE stained histological images of animal lungs treated for 7 consecutive days with different formulations. a) Untreated; b) CIPR treated; c) AgLase treated; d) CIPR-CH-NPs treated and; e) AgLase-CIPR-CH-NPs treated **107**